Oculomucocutaneous syndrome

Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]

References

  1. ↑ Wright, P (Mar 15, 1975). "Untoward effects associated with practolol administration: oculomucocutaneous syndrome.". British Medical Journal. 1 (5958): 595–8. doi:10.1136/bmj.1.5958.595. PMC 1672788Freely accessible. PMID 1125623.
  2. ↑ Amos, HE; Lake, BG; Artis, J (Feb 18, 1978). "Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome.". British Medical Journal. 1 (6110): 402–4. doi:10.1136/bmj.1.6110.402. PMC 1602979Freely accessible. PMID 146533.


This article is issued from Wikipedia - version of the 8/30/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.